Other languages Kane Biotech Inc.

Equities

KNE

CA4838092084

Delayed Toronto S.E. Other stock markets 09:40:43 2024-05-09 am EDT			5-day change	1st Jan Change
0.14 ^CAD	0.00%		+7.69%	+75.00%

Apr. 18	Transcript : Kane Biotech Inc. - Special Call
Apr. 15	Kane Biotech Up 12% After Reporting Closing of STEM Animal Health Sale	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Dechra Veterinary Products, Inc. completed the acquisition of 66.66% stake in STEM Animal Health Inc. from Kane Biotech Inc..	Apr. 14
Kane Biotech Agrees to Sell its Interest in STEM Animal Health for US$8 Million	Apr. 11
Kane Biotech Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 26
Kane Biotech Extends Exclusivity Period on its Offer for its Interest in STEM Animal Health	Mar. 20
Kane Biotech Inc. Appoints Dr. Robert Huizinga as Director and Executive Chair	Feb. 22
Kane Biotech Inc. Files New Patent on Revyvetm Antimicrobial Wound Gel Spray	Jan. 31
Kane Biotech Announces Correction to Press Release	Dec. 29
Kane Biotech Third-Quarter Loss Widens Despite Improved Revenue	Nov. 28
Kane Biotech Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 28
Kane Biotech Inc. Appoints John Coleman to the Board of Directors	Nov. 16
Kane Biotech Inc. and ProgenaCare Global Launch Newly Rebranded Revyve Antimicrobial Wound Care Fall Forum	Nov. 02
Kane Biotech Inc. to Exhibit At Symposium on Advanced Wound Care Fall Forum	23-10-25
Kane Biotech Second-Quarter Loss Widens Even as Revenue Rises 68%	23-08-29
Kane Biotech Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-28
Kane Biotech Engages Research Capital to Conduct Strategic Review of STEM Animal Health	23-08-02
Kane Biotech Engages Research Capital to Conduct Strategic Review of Stem Animal Health	23-08-02
Kane Biotech Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-29
Kane Biotech Q1 Loss Widens; Receives FDA Approval for Wound-Care Product	23-05-25
Kane Biotech Inc. Announces FDA 510(k) Clearance for its Coactiv+™? Antimicrobial Wound Gel	23-05-25
Kane Biotech Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-20

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Kane Biotech Inc.

Equities

KNE

CA4838092084

Other languages

Filters